Webinar: The top medtech stories of 2017 – Jan. 30

Tuesday, January 30, 2018 2:00pm ET / 11:00 PT     The medtech industry saw its transformation accelerate in 2017: Whether it’s the roster of largest companies, business models or the regulatory environment, times are a-changing. Competition is also heating up in areas including diabetes care and robotic surgery. MDO’s managing editor Chris Newmarker will

7 top stories that mattered for medtech in 2017

The medtech industry saw its transformation accelerate in 2017: Whether it’s the roster of largest companies, business models or the regulatory environment, times are a-changing. Competition is also heating up in areas including diabetes care and robotic surgery. Here are seven stories that mattered for the medical device industry this year. Next>>

Pages: 1 2 3 4 5 6 7 8

DeviceTalks West: Here are the speakers you’ll see

Hundreds of medical device industry insiders are expected to descend on Orange County, Calif., this month for DeviceTalks West – a premier boutique networking and learning event. From the VP in charge of Medtronic’s neurovascular business to the artificial pancreas pioneer Jeffrey Brewer, here are some of the speakers you’ll meet at DeviceTalks West, Dec. 11–12

Pages: 1 2 3 4 5 6 7 8

Bigfoot Biomedical CEO hits back against CMS over data-sharing decision

Bigfoot Biomedical CEO Jeffrey Brewer has spoken out about a recent data-sharing decision made by CMS, saying that he plans to lobby Medicare to reverse its latest move. Earlier this year, CMS said it would begin covering the use of particular continuous glucose monitors for people with diabetes. But since that decision, the agency has […]

Why Bigfoot Biomedical’s CEO thinks the diabetes industry has a data problem

Bigfoot Biomedical‘s chief executive is excited about Abbott‘s (NYSE:ABT) latest regulatory win – and it’s not just because the two companies have an established partnership. Yesterday, the FDA approved Abbott’s FreeStyle Libre Flash continuous glucose monitoring system. It’s the first device of its kind, allowing patients to track their blood glucose levels without the use […]

Why Abbott’s CEO is excited about Bigfoot Biomedical and diabetes treatment

Just one week after Abbott (NYSE:ABT) said it inked a deal with Bigfoot Biomedical to develop an automated diabetes management system, CEO Miles White told analysts that he thinks Bigfoot is playing an important role in the strategic change taking place in the space. “It’s a fairly clever service and approach that I think will create, not just an

How Bigfoot Biomedical wants to disrupt diabetes care

Bigfoot Biomedical is a highly competitive player in medtech’s race to develop an artificial pancreas. The 50-person company has made rapid progress towards developing a smart, automated insulin delivery system since its beginnings in 2014. Just yesterday Bigfoot announced that it is partnering with Abbott, bringing together Abbott’s FreeStyle Libre glucose monitoring tech and Bigfoot’s insulin

Artificial pancreas: These companies are racing to make one

Medical device companies are close to achieving the holy grail of diabetes treatment: a combined glucose sensor, control algorithm and insulin infusion device that effectively acts as an “artificial pancreas.” We explain more in our newest Medical Design & Outsourcing video. (And for a deeper dive, check out our recent roundup of companies in the

7 companies in the race to make an artificial pancreas

Over 50 years ago, scientists discovered the ability to externally control blood glucose regulation for individuals with type 1 diabetes. Since then, researchers in the field of diabetes management have dreamt of creating a closed-loop system – a combined glucose sensor, control algorithm and insulin infusion device – to effectively act as an “artificial pancreas”

Pages: 1 2 3 4 5 6 7 8 9